surpris salesforc report solid result
mix busi trend like keep show-m
stock head
acr takeaway rise tide jak inhibit
lupu data could leader pack
spa secur addit retin indic
investor day follow-up optum take lead
strong gate
macro uncertainti keep us sidelin
analyst certif import disclosur see
surpris salesforc report solid result
salesforc deliv solid result owe broad-bas busi strength product region vertic rais
tableau revenu guidanc quarter result busi outlook essenti line expect
come last month investor meet neg manag guid growth deceler y/i
versu ytd despit easier y/i comparison bottom line believ salesforc book
momentum like show better trend tableau put compani stronger posit becom vendor
choic digit transform initi among larg install-bas howev posit fulli reflect
mix busi trend like keep show-m stock head
workday mark strong cash gener commentari abil workday financi gain enterpris
share off-set slowdown lead indic upon reflect align custom survey trend
bottom line result unlik chang narr workday plenti nois surround
slowdown compani hcm growth believ manag fundament make right decis emphas
suit approach financi plan analyt procur catalyz opportun share gain longer-
term investor could find entic share trade line saa industri averag believ workday
trade premium group consid larger greater gener maintain outperform
acr takeaway rise tide jak inhibit
attend american colleg rheumatolog acr meet held novemb
provid key takeaway coverag univers full report releas notabl ra space heard updat
experi jak inhibit jaki result emerg jak therapi gild/glpg filgotinib
upadacitinib investor focu hone perhap myopic likelihood filgotinib receiv black
box warn similar upadacitinib note diverg greatli observ physician commun quit
comfort adopt emerg class therapi despit fda current cautiou approach provid
thought filgotinib commerci opportun specif could differenti potenti blockbust franchis
recent launch coverag share invest rate outperform
month price target note repres nich player up-and-com within burgeon
consum healthcar space compani proprietari ingredi niagen demonstr signific promis mean
allow peopl age better among attribut share remain radar mani investor
report date quickli outlin number recent posit develop compani core product
construct call longer term highli specul natur
past two day spent time ceo chri brickman presid salli beauti suppli cfo aaron alt
compani comment busi trend intra-quart overal walk away confid potenti
compani transform effort take hold time recent quarter manag aggress invest
busi technolog store develop new capabl improv competit posit evolv
omni-channel backdrop sb deliv comp increas us/canada suggest traction initi effort
turnaround cover progress typic linear seem right path go forward
includ top ten takeaway full report date
lupu data could leader pack
announc posit top-lin result lilac lupu studi blood dendrit cell antigen
antibodi lilac part posit system lupu erythematosu sle activ joint skin manifest
patient part improv total activ joint count week bl part dose
multipl secondari endpoint also suggest improv overal diseas activ activ cutan lupu erythematosu
cle includ chronic subacut subtyp part improv clasi-a score week
depend dose vs placebo anifrolumab azn target interferon receptor downstream
data lupu area high unmet need limit option detail full report publish
spa secur addit retin indic
special protocol assess spa obtain futur registr studi two common retin disord brvo dme
pave way broad eventu label ophthalm formul bevacizumab/avastin also
provid clariti otlk abil protect anticip anti-vegf ophthalmolog franchis top line data on-going
phase trial wet track like enabl earli launch believ posit
swift adopt initi step therapi ahead expens anti-vegf lucenti eylea beovu consid health risk
pose steril inject compound regulatori tailwind given enterpris valu see otlk share
under-valued mind need increas cash balanc ahead upcom clinic readout
investor day follow-up optum take lead
host annual investor confer continu highlight compani bright prospect
driven larg growth optum medicar advantag cost-trend remain stabl compani issu ep
guidanc impli growth exclud impact hif conserv remain
low end long-term ep growth rate target growth driven optum project
slightli surpass unitedhealthcar term segment earn contribut compani also tweak ep
guidanc approach compar previous overal remain well posit leverag
well round servic offer elit manag team industry-lead scale result maintain outperform
strong gate
marvel report in-lin oct result tuesday sales/ep jan outlook
mix includ contribut recent acquir aq/avera also connect sale nxpi receiv
regulatori approv expect close within week exclud aq/avera sale outlook would
vs season upsid came much anticip ramp lead bt custom samsung
purest infrastructur play estim samsung content bt year life-cycle
see nok/er bt ramp next year well like aq/avera acquisit sale non-core/low
margin connect remain buyer price target
advanc talk habana lab acquisit billion ctech
akousti receiv first network infrastructur filter order custom small cell architectur
macro uncertainti keep us sidelin
report ep vs estim miss driven weaker anticip revenu
segment industri margin partli off-set higher engin profit favor tax rate anticip
demand trend remain uneven soft new equip order resili replac part notabl
growth certain area portfolio process filtrat maintain guidanc includ sale
y/i ep y/i applaud execut amid uncertain demand backdrop highlight
gross margin progress remain cautiou macro variabl ep inflect contempl guidanc
see potenti expect move lower come quarter
may biotech summit featur chemistri life process institutechicago
